The etiology and molecular genetics of human pigmentation disorders

Wiley Interdisciplinary Reviews: Developmental Biology

Volumn 2, Issue 3, 2013, Pages 379-392

  Baxter, Laura L ^a   Pavan, William J ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI PROTEIN; INTERFERON REGULATORY FACTOR 4; MELANOCORTIN 1 RECEPTOR; MONOPHENOL MONOOXYGENASE; STEM CELL FACTOR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR SOX10; TYROSINASE RELATED PROTEIN 1;

CELL PROLIFERATION; CHEDIAK HIGASHI SYNDROME; FANCONI ANEMIA; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPE PHENOTYPE CORRELATION; GRISCELLI SYNDROME; HEREDITY; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LEOPARD SYNDROME; MELANOCYTIC NEVUS; MELANOCYTOSIS; MOLECULAR GENETICS; NEURAL CREST CELL; NOONAN SYNDROME; OCULOCUTANEOUS ALBINISM; PEUTZ JEGHERS SYNDROME; PHENOTYPE; PIGMENT DISORDER; REVIEW; SEQUENCE ANALYSIS; SKIN COLOR; SKIN PIGMENTATION; WAARDENBURG SYNDROME;

AGOUTI SIGNALING PROTEIN; ALBINISM, OCULOCUTANEOUS; CALCIUM CHANNELS; HUMANS; INTERFERON REGULATORY FACTORS; MEMBRANE TRANSPORT PROTEINS; MONOPHENOL MONOOXYGENASE; PAIRED BOX TRANSCRIPTION FACTORS; PIGMENTATION DISORDERS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, MELANOCORTIN, TYPE 1; TRANSCRIPTION FACTORS;

EID: 84886253632     PISSN: 17597684     EISSN: 17597692     Source Type: Journal    
DOI: 10.1002/wdev.72     Document Type: Review

References (85)

1. Thomas I, Kihiczak GG, Fox MD, Janniger CK, Schwartz RA. Piebaldism: an update. Int J Dermatol 2004, 43:716-719.
2. Thomas AJ, Erickson CA. The making of a melanocyte: the specification of melanoblasts from the neural crest. Pigment Cell Melanoma Res 2008, 21:598-610.
3. Adameyko I, Lallemend F, Aquino JB, Pereira JA, Topilko P, Müller T, Fritz N, Beljajeva A, Mochii M, Liste I, et al. Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell 2009, 139:366-379.
4. Kelsh RN, Harris ML, Colanesi S, Erickson CA. Stripes and belly-spots-a review of pigment cell morphogenesis in vertebrates. Semin Cell Dev Biol 2009, 20:90-104.
5. Luciani F, Champeval D, Herbette A, Denat L, Aylaj B, Martinozzi S, Ballotti R, Kemler R, Goding CR, De Vuyst F, et al. Biological and mathematical modeling of melanocyte development. Development 2011, 138:3943-3954.
6. Sturm RA. Molecular genetics of human pigmentation diversity. Hum Mol Genet 2009, 18:R9-17.
7. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995, 11:328-330.
8. Beaumont KA, Shekar SN, Cook AL, Duffy DL, Sturm RA. Red hair is the null phenotype of MC1R. Hum Mutat 2008, 29:E88-94.
9. Bharti K, Nguyen M-TT, Skuntz S, Bertuzzi S, Arnheiter H. The other pigment cell: specification and development of the pigmented epithelium of the vertebrate eye. Pigment Cell Res 2006, 19:380-394.
10. Hennekam RC, Gorlin RJ. Confirmation of the Yemenite (Warburg) deaf-blind hypopigmentation syndrome. Am J Med Genet 1996, 65:146-148.
11. Bondurand N, Kuhlbrodt K, Pingault V, Enderich J, Sajus M, Tommerup N, Warburg M, Hennekam RC, Read AP, Wegner M, et al. A molecular analysis of the yemenite deaf-blind hypopigmentation syndrome: SOX10 dysfunction causes different neurocristopathies. Hum Mol Genet 1999, 8:1785-1789.
12. Izumi K, Kohta T, Kimura Y, Ishida S, Takahashi T, Ishiko A, Kosaki K. Tietz syndrome: unique phenotype specific to mutations of MITF nuclear localization signal. Clin Genet 2008, 74:93-95.
13. Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N. Review and update of mutations causing Waardenburg syndrome. Hum Mutat 2010, 31:391-406.
14. Inoue K, Khajavi M, Ohyama T, Hirabayashi S-I, Wilson J, Reggin JD, Mancias P, Butler IJ, Wilkinson MF, Wegner M, et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet 2004, 36:361-369.
15. Bondurand N, Dastot-Le Moal F, Stanchina L, Collot N, Baral V, Marlin S, Attie-Bitach T, Giurgea I, Skopinski L, Reardon W, et al. Deletions at the SOX10 gene locus cause Waardenburg syndrome types 2 and 4. Am J Hum Genet 2007, 81:1169-1185.
16. Chaoui A, Watanabe Y, Touraine R, Baral V, Goossens M, Pingault V, Bondurand N. Identification and functional analysis of SOX10 missense mutations in different subtypes of Waardenburg syndrome. Hum Mutat 2011, 32:1436-1449.
17. Corry GN, Hendzel J, Underhill DA. Subnuclear localization and mobility are key indicators of PAX3 dysfunction in Waardenburg syndrome. Hum Mol Genet 2008, 17:1825-1837.
18. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008, 9:359-386.
19. Cullinane AR, Curry JA, Carmona-Rivera C, Summers CG, Ciccone C, Cardillo ND, Dorward H, Hess RA, White JG, Adams D, et al. A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak syndrome type 9. Am J Hum Genet 2011, 88:778-787.
20. Plonka PM, Passeron T, Brenner M, Tobin DJ, Shibahara S, Thomas A, Slominski A, Kadekaro AL, Hershkovitz D, Peters E, et al. What are melanocytes really doing all day long..?. Exp Dermatol 2009, 18: 799-819.
21. Nordlund JJ. The melanocyte and the epidermal melanin unit: an expanded concept. Dermatol Clin 2007, 25:271-281, vii.
22. Quevedo WC. Epidermal melanin units: melanocyte-keratinocyte interactions. Am Zoologist 1972, 12: 35-41.
23. Taieb A, Boralevi F. Hypermelanoses of the newborn and of the infant. Dermatol Clin 2007, 25:327-336, viii.
24. Schaffer JV. Pigmented lesions in children: when to worry. Curr Opin Pediatr 2007, 19:430-440.
25. Fistarol SK, Itin PH. Disorders of pigmentation. J German Soc Dermatol 2010, 8:187-201.
26. Rajpara SM, Botello AP, Townend J, Ormerod AD. Systematic review of dermoscopy and digital dermoscopy/ artificial intelligence for the diagnosis of melanoma. Br J Dermatol 2009, 161:591-604.
27. Elder DE. Precursors to melanoma and their mimics: nevi of special sites. Mod Pathol 2006, 19(suppl 2):S4-20.
28. McGregor B, Pfitzner J, Zhu G, Grace M, Eldridge A, Pearson J, Mayne C, Aitken JF, Green AC, Martin NG. Genetic and environmental contributions to size, color, shape, and other characteristics of melanocytic naevi in a sample of adolescent twins. Genet Epidemiol 1999, 16:40-53.
29. Zhu G, Duffy DL, Eldridge A, Grace M, Mayne C, O'Gorman L, Aitken JF, Neale MC, Hayward NK, Green AC, et al. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet 1999, 65:483-492.
30. Wachsmuth RC, Gaut RM, Barrett JH, Saunders CL, Randerson-Moor JA, Eldridge A, Martin NG, Bishop TD, Newton Bishop JA. Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol 2001, 117:348-352.
31. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JAN, Pastinen T, Cervino A, Zhao ZZ, Deloukas P, Soranzo N, et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009, 41:915-919.
32. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011, 24:879-897.
33. Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res 2003, 16:297-306.
34. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005, 41:28-44.
35. Zayour M, Lazova R. Congenital melanocytic nevi. Clin Lab Med 2011, 31:267-280.
36. Hale EK, Stein J, Ben-Porat L, Panageas KS, Eichenbaum MS, Marghoob AA, Osman I, Kopf AW, Polsky D. Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi-results from the NYU-LCMN registry. Br J Dermatol 2005, 152:512-517.
37. Hafner C, Stoehr R, van Oers JMM, Zwarthoff EC, Hofstaedter F, Landthaler M, Hartmann A, Vogt T. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo. Br J Dermatol 2009, 160:546-551.
38. Nordlund JJ, Lerner AB, Braverman IM, McGuire JS. The multiple lentigines syndrome. Arch Dermatol 1973, 107:259-261.
39. Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002, 71: 389-394.
40. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007, 39: 1007-1012.
41. Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat 2009, 30:695-702.
42. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006, 281:6785-6792.
43. Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, Hurley AD, Bentires-Alj M, Fisher DE, Kontaridis MI, Look AT, et al. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell 2010, 18:750-762.
44. Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 2011, 25:161-179.
45. Zembowicz A, Mihm MC. Dermal dendritic melanocytic proliferations: an update. Histopathology 2004, 45:433-451.
46. Reza AM, Farahnaz GZ, Hamideh S, Alinaghi SAS, Saeed Z, Mostafa H. Incidence of Mongolian spots and its common sites at two university hospitals in Tehran, Iran. Pediatr Dermatol 2010, 27:397-398.
47. Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG, Ellis N, Besmer P, Brennan M, Offit K. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 2004, 10:1250-1254.
48. Campbell T, Felsten L, Moore J. Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome. Arch Dermatol 2009, 145:1313-1316.
49. Rothenbuhler A, Stratakis CA. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab 2010, 24:389-399.
50. Okazaki M, Yoshimura K, Suzuki Y, Uchida G, Kitano Y, Harii K, Imokawa G. The mechanism of epidermal hyperpigmentation in café-au-lait macules of neurofibromatosis type 1 (von Recklinghausen's disease) may be associated with dermal fibroblast-derived stem cell factor and hepatocyte growth factor. Br J Dermatol 2003, 148:689-697.
51. De Schepper S, Boucneau J, Vander Haeghen Y, Messiaen L, Naeyaert J-M, Lambert J. Café-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpigmentation of a different kind? Arch Dermatol Res 2006, 297:439-449.
52. Amyere M, Vogt T, Hoo J, Brandrup F, Bygum A, Boon L, Vikkula M. KITLG mutations cause familial progressive hyper- and hypopigmentation. J Invest Dermatol 2011, 131:1234-1239.
53. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009, 19:230-236.
54. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010, 42: 794-800.
55. Pérez B, Mechinaud F, Galambrun C, Ben Romdhane N, Isidor B, Philip N, Derain-Court J, Cassinat B, Lachenaud J, Kaltenbach S, et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet 2010, 47:686-691.
56. Vachiramon V. Approach to reticulate hyperpigmentation. Clin Exp Dermatol 2011, 36:459-466.
57. Spritz RA. Recent progress in the genetics of generalized vitiligo. J Genet Genomics 2011, 38:271-278.
58. Koga M, Tango T. Clinical features and course of type A and type B vitiligo. Br J Dermatol 1988, 118:223-228.
59. van den Boorn JG, Konijnenberg D, Dellemijn TAM, van der Veen JPW, Bos JD, Melief CJM, Vyth-Dreese FA, Luiten RM. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009, 129:2220-2232.
60. Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P, Ruiz-Argüelles A. Immunopathogenesis of vitiligo. Autoimmun Rev 2011, 10:762-765.
61. Bastiaens M, Huurne ter J, Gruis N, Bergman W, Westendorp R, Vermeer BJ, Bouwes Bavinck JN. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet 2001, 10:1701-1708.
62. English DR, Armstrong BK. Melanocytic nevi in children. I. Anatomic sites and demographic and host factors. Am J Epidemiol 1994, 139:390-401.
63. Fritschi L, McHenry P, Green A, Mackie R, Green L, Siskind V. Naevi in schoolchildren in Scotland and Australia. Br J Dermatol 1994, 130:599-603.
64. Harrison SL, MacKie RM, MacLennan R. Development of melanocytic nevi in the first three years of life. J Natl Cancer Inst 2000, 92:1436-1438.
65. Whiteman DC, Brown RM, Purdie DM, Hughes M-C. Melanocytic nevi in very young children: the role of phenotype, sun exposure, and sun protection. J Am Acad Dermatol 2005, 52:40-47.
66. Hattori H, Kawashima M, Ichikawa Y, Imokawa G. The epidermal stem cell factor is over-expressed in lentigo senilis: implication for the mechanism of hyperpigmentation. J Invest Dermatol 2004, 122: 1256-1265.
67. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602.
68. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363: 2191-2199.
69. Stulberg DL, Clark N, Tovey D. Common hyperpigmentation disorders in adults: Part II. Melanoma, seborrheic keratoses, acanthosis nigricans, melasma, diabetic dermopathy, tinea versicolor, and postinflammatory hyperpigmentation. Am Fam Physician 2003, 68:1963-1968.
70. Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg 1997, 16:36-43.
71. Kunisada T, Yoshida H, Yamazaki H, Miyamoto A, Hemmi H, Nishimura E, Shultz LD, Nishikawa S, Hayashi S. Transgene expression of steel factor in the basal layer of epidermis promotes survival, proliferation, differentiation and migration of melanocyte precursors. Development 1998, 125:2915-2923.
72. Kunisada T, Yamazaki H, Hirobe T, Kamei S, Omoteno M, Tagaya H, Hemmi H, Koshimizu U, Nakamura T, Hayashi SI. Keratinocyte expression of transgenic hepatocyte growth factor affects melanocyte development, leading to dermal melanocytosis. Mech Dev 2000, 94:67-78.
73. Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J Vis Exp 2011, 54:2937. doi:10.3791/2937.
74. Murakami T, Hosomi N, Oiso N, Giovannucci-Uzielli ML, Aquaron R, Mizoguchi M, Kato A, Ishii M, Bitner-Glindzicz M, Barnicoat A, et al. Analysis of KIT, SCF, and initial screening of SLUG in patients with piebaldism. J Invest Dermatol 2005, 124:670-672.
75. Toriello HV. Pigmentary anomalies and hearing loss. Adv Otorhinolaryngol 2011, 70:50-55.
76. Zlotogora J. X-linked albinism-deafness syndrome and Waardenburg syndrome type II: a hypothesis. Am J Med Genet 1995, 59:386-387.
77. Bashiti HM, Blair JD, Triska RA, Keller L. Generalized dermal melanocytosis. Arch Dermatol 1981, 117: 791-793.
78. Schwartz RA, Cohen-Addad N, Lambert MW, Lambert WC. Congenital melanocytosis with myelomeningocele and hydrocephalus. Cutis 1986, 37:37-39.
79. Happle R. What is a nevus? A proposed definition of a common medical term. Dermatology (Basel) 1995, 191:1-5.
80. Torrelo A, Baselga E, Nagore E, Zambrano A, Happle R. Delineation of the various shapes and patterns of nevi. Eur J Dermatol 2005, 15:439-450.
81. Li L, Fukunaga-Kalabis M, Yu H, Xu X, Kong J, Lee JT, Herlyn M. Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci 2010, 123: 853-860.
82. Cramer SF. Stem cells for epidermal melanocytes-a challenge for students of dermatopathology. Am J Dermatopath 2009, 31:331-341.
83. Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne JP. The Pigmentary System: Physiology and Pathophysiology. Malden, Massachusetts: Blackwell Publishing; 2006.
84. The Online Metabolic and Molecular Bases of Inherited Disease
85. Online Mendelian Inheritance in Man